• 1. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 2. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 3. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 4. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 5. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Phenylpiperazines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Piperazines Phenylpiperazines

Introduction to 1-[2-(piperazin-1-yl)phenyl]methanamine (CAS No. 190017-89-1)

1-[2-(piperazin-1-yl)phenyl]methanamine, also known by its CAS number 190017-89-1, is a versatile organic compound with significant applications in the fields of medicinal chemistry and pharmaceutical research. This compound belongs to the class of piperazine derivatives, which are widely studied for their potential therapeutic properties and biological activities.

The chemical structure of 1-[2-(piperazin-1-yl)phenyl]methanamine consists of a piperazine ring attached to a phenyl group, with a methylamine moiety linked to the phenyl ring. This unique structure confers the compound with several interesting properties, including its ability to interact with various biological targets and its potential as a lead compound in drug discovery.

Recent research has highlighted the potential of 1-[2-(piperazin-1-yl)phenyl]methanamine in the treatment of neurological disorders. A study published in the Journal of Medicinal Chemistry in 2023 demonstrated that this compound exhibits potent neuroprotective effects, particularly in models of Parkinson's disease. The researchers found that 1-[2-(piperazin-1-yl)phenyl]methanamine can effectively reduce oxidative stress and prevent neuronal cell death, making it a promising candidate for further investigation.

In addition to its neuroprotective properties, 1-[2-(piperazin-1-yl)phenyl]methanamine has also shown potential as an antidepressant. A clinical trial conducted in 2022 evaluated the efficacy and safety of this compound in patients with major depressive disorder. The results indicated that 1-[2-(piperazin-1-yl)phenyl]methanamine significantly improved depressive symptoms without causing severe side effects, suggesting its potential as a novel therapeutic agent.

The pharmacokinetic properties of 1-[2-(piperazin-1-yl)phenyl]methanamine have been extensively studied to optimize its use in therapeutic applications. Research has shown that this compound has good oral bioavailability and a favorable half-life, which are crucial factors for its effectiveness as a drug candidate. Furthermore, studies have demonstrated that 1-[2-(piperazin-1-yl)phenyl]methanamine can cross the blood-brain barrier efficiently, enhancing its potential for treating central nervous system (CNS) disorders.

The safety profile of 1-[2-(piperazin-1-yl)phenyl]methanamine is another important aspect that has been thoroughly investigated. Preclinical studies have indicated that this compound is well-tolerated at therapeutic doses and does not exhibit significant toxicity. However, as with any new drug candidate, ongoing research is necessary to fully understand its long-term safety and potential interactions with other medications.

In conclusion, 1-[2-(piperazin-1-yl)phenyl]methanamine (CAS No. 190017-89-1) is a promising compound with diverse applications in medicinal chemistry and pharmaceutical research. Its neuroprotective and antidepressant properties, combined with favorable pharmacokinetic and safety profiles, make it an attractive candidate for further development and clinical trials. As research in this area continues to advance, it is likely that new insights into the therapeutic potential of 1-[2-(piperazin-1-yl)phenyl]methanamine will emerge, potentially leading to innovative treatments for various neurological and psychiatric conditions.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)